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Background: The amyloid-β peptide (Aβ42) is the main component of the inter-neuronal amyloid plaques
characteristic of Alzheimer's disease (AD). The mechanism by which Aβ42 and other amyloid peptides assemble
into insoluble neurotoxic deposits is still not completely understood and multiple factors have been reported to
trigger their formation. In particular, the presence of endogenous metal ions has been linked to the pathogenesis
of AD and other neurodegenerative disorders.
Results: Here we describe a rapid and high-throughput screening method to identify molecules able to modulate
amyloid aggregation. The approach exploits the inclusion bodies (IBs) formed by Aβ42 when expressed in bacteria.
We have shown previously that these aggregates retain amyloid structural and functional properties. In the present
work, we demonstrate that their in vitro refolding is selectively sensitive to the presence of aggregation-promoting
metal ions, allowing the detection of inhibitors of metal-promoted amyloid aggregation with potential therapeutic
interest.
Conclusions: Because IBs can be produced at high levels and easily purified, the method overcomes one of the
main limitations in screens to detect amyloid modulators: the use of expensive and usually highly insoluble
synthetic peptides.
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In the last few years, protein aggregation has emerged from
a neglected area of protein chemistry as a transcendental
issue in biological and medical sciences, mainly because
the deposition of proteins into insoluble amyloid fibrils is
being found behind an increasing number of human dis-
eases such as Alzheimer’s disease (AD) or type II diabetes
[1–4]. Therefore, there is an increasing interest in develop-
ing methods to identify molecules that trigger the aggrega-
tion of these proteins inside the organism as well as to
discover chemical compounds that can interfere with these
pathways, having thus therapeutic potential [5–7].
The pathological hallmark of AD is brain deposition of
amyloid plaques composed predominantly by the Aβ42
peptide isoform [8–10]. The origin of these insoluble* Correspondence: salvador.ventura@uab.es
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distribution, and reproduction in any mediumextracellular neurotoxic deposits is still not completely
clear, and multiple factors such as pH, peptide concentra-
tion, oxidative stress and metal ions have been reported to
trigger their formation [11,12]. Here we present a fast,
cost-effective high-throughput approach to study condi-
tions and molecules that affect Aβ42 aggregation. The
assay is based on the use of the inclusion bodies (IBs)
formed by an Aβ42-GFP fusion protein in bacteria. IBs for-
mation has long been regarded as an unspecific process
relaying on the establishment of hydrophobic contacts
[13,14]. However, there are now strong evidences demon-
strating that bacterial IBs formation shares a number of
common features with the formation of the highly ordered
and pathogenic amyloid fibrils linked to human diseases
[15–18]. Therefore, IBs have become an attractive model
to study protein aggregation and their consequences in
simple but biologically relevant environments [19–21]. IBs
are formed inside the cell when the folding of proteins into
native conformations is competed by a faster establishment
of anomalous intermolecular interactions that leads to the
formation of insoluble aggregates [22]. In the present work,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.microbialcellfactories.com/content/11/1/55we exploit this kinetic competition in vitro to screen for
compounds that can modulate protein aggregation. As a
proof of principle, we demonstrate the ability of the ap-
proach to detect the effect of metal ions on Aβ42 aggrega-
tion as well as to identify compounds that block this
metal-induced reaction.
Results and Discussion
Refolding Aβ42-GFP IBs is sequence specific
We have previously shown that the IBs formed by Aβ42
display amyloid-like properties whether the peptide is
expressed alone [23] or fused to fluorescent proteins0
1.5×107
1.0×107
5.0×106
0
3.0×103
A
2.0×107
Aβ42wt-GFP
B
2.5×103
2.0×103
1.5×103
1.0×103
5.0×102
3.5×103
Fl
u
o
re
s
c
en
c
e
 
em
is
si
o
n
 
at
 
51
0 
nm
 
 
(a.
u
.
)
Fl
u
o
re
s
c
en
c
e
 
em
is
si
o
n
 
at
 
51
0 
nm
 
 
(a.
u
.
)
native denatured dena
(urea) (Gu·
native denatured denatured
(urea) (Gu·HCl)
GFP
Figure 1 Fluorescence recovery after denaturation. (A) Purified IBs were
10 M urea for 4 h and diluted 100-fold in PBS. (B) Purified untagged GFP (left
presence of 8 M GuHCl or 10 M urea for 4 h and diluted 100-fold in PBS. In a[16,24]. We have constructed a set of 20 different Aβ42–
GFP variants, which differ only in a single residue in the
peptide’s central hydrophobic region [25]. All these pro-
teins are expressed at similar levels in E. coli and form in-
soluble IBs [25]. Nevertheless, the fraction of active GFP
in those aggregates is significantly different (Figure 1). The
IBs fluorescence correlates with the aggregation propen-
sity of the specific Aβ42 mutant [26]. This correlation is
the result of a kinetic competition between the folding of
the GFP domain and the aggregation of the fusion protein,
which is driven by the Aβ42 moiety. Therefore, the slower
the fusion protein aggregates, the higher the IB fluorescenceAβ42F19D-GFP
tured denatured denatured
HCl)
native denatured denatured
(urea) (Gu·HCl)
(urea) (Gu·HCl)
Aβ42wt-GFP
incubated in PBS in the absence (native) and presence of 8 M GuHCl or
) and IBs (right) were incubated in PBS in the absence (native) and
ll cases, after incubation for 16 h fluorescence was recorded at 510 nm.
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http://www.microbialcellfactories.com/content/11/1/55emission is and vice versa. In this way, IBs fluorescence
reports on intracellular aggregation kinetics [22,26,27].
We wondered if the kinetic competition between GFP
folding and Aβ42 aggregation can be reproduced
in vitro. To this aim we used the IBs formed by the
wild-type peptide fusion (Aβ42wt-GFP) and the F19D
mutant (Aβ42F19D-GFP), which display the highest and
lowest aggregation propensities in our library, respect-
ively [22]. Purified IBs were denatured to remove the
polypeptide contacts supporting the aggregate structure.
This provides unfolded and isolated species for the sub-
sequent in vitro refolding step and guarantees that allA
54.0×10
3.0×105
2.0×105
51.0×10
Fl
u
o
re
s
ce
n
c
e
 
e
m
is
si
o
n
 a
t 5
10
 
n
m
 (a
.
u
.) 
Fl
u
o
re
s
ce
n
c
e
 
e
m
is
si
o
n
 a
t 5
10
 
n
m
 (a
.
u
.) 
tro
l +2
a
+3
e
+g
0
co
n C F M
B
3.5×103
3.0×103
2 5×103.
2.0×103
1.5×103
1 0×103.
5.0×102
0
native               native + Zn2+      
Figure 2 Fluorescence recovery in the presence of metallic ions. (A) A
fold in PBS (control) or in PBS containing different metallic ions at 25 μM fi
in PBS in the absence (native) and presence of 8 M GuHCl for 4 h and dilu
concentration. In all cases, after incubation for 16 h fluorescence was recorinter- or intra-molecular contacts are established de
novo as it happens after protein synthesis in the cell. IBs
were chemically denatured using two chaotropic agents,
10 M urea and 8 M GuHCl. Each unfolded Aβ42-GFP
fusion was diluted in refolding buffer and the amount of
recovered active GFP monitored using fluorescence
spectroscopy (see Methods). The same conditions were
used to unfold and refold equimolar concentrations of
native untagged GFP. As it can be seen in Figure 1A, in-
dependently of the IBs peptide variant, the level of
recovered GFP activity was higher when GuHCl was
used as denaturant. This is in contrast with the results2 +1
a
+2i +
2
n
+2
uN N Z C
   native + Cu2+ denatured             denatured
    + Zn2+                  + Cu2+
β42wt-GFP IBs were denatured in 8 M GuHCl for 4 h and diluted 100-
nal concentration. (B) Purified untagged GFP and IBs were incubated
ted 100-fold in PBS containing Cu+2 and Zn+2 at 25 μM final
ded at 510 nm.
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http://www.microbialcellfactories.com/content/11/1/55obtained with untagged GFP, for which denaturation with
urea resulted in higher fluorescence recovery (Figure1B),
suggesting that the used denaturant might affect the aggre-
gation/refolding pathway. The proportion of fluorescentIBs Aβ42wt-GFP
A
1 µm
1 µm
B
IBs refolded in PBS+Zn2+
Figure 3 Morphology and secondary structure of aggregates. (A) Mor
absence and presence Cu+2 and Zn+2. (B) Analysis of the secondary structu
Cu+2 and Zn+2 by FT-IR spectroscopy in the amide I region of the spectra.GFP recovered after refolding was always higher than
that in the original IB (Figure 1A). Aggregation usually
corresponds to a second or higher order reaction and
therefore, aggregation rates are extremely dependentIBs refolded in PBS
1 µm
1 µm
IBs refolded in PBS+Cu2+
phology of purified IBs and aggregates in refolding solutions in the
re of aggregates in refolding solutions in the absence and presence
The spectrum of native GFP is shown as a control.
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Figure 4 Effect of metallic ion concentrations on fluorescence
recovery. Aβ42wt-GFP IBs were denatured in 8 M GuHCl for 4 h
and the relative GFP fluorescence recovery upon refolding in the
presence of increasing concentrations of Cu+2 and Zn+2 was
monitored at 510 nm.
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centrations used during in vitro refolding are much lower
than those existent in vivo, the folding of the GFP domain
can compete more efficiently with the aggregation
process, providing a larger dynamic response than in bac-
teria. However, the refolding efficiency of Aβ42-GFP IBs is
about ~10-fold and ~4-fold lower than this of untagged
GFP after denaturation in urea and GuHCl, respectively,
suggesting that, as it happens in vivo, the aggregation of
the Aβ42 moiety competes the folding of GFP. Import-
antly, the activity recovery from the mutant IBs is higher
than that from IBs formed by the wild-type sequence, sup-
porting a kinetic competition between GFP folding and
Aβ42 aggregation in vitro. The predicted lower aggrega-
tion rate of the mutant would account for the higher fluor-
escence recovery. By analogy, any agent that would
increase the intrinsic aggregation rate of Aβ42 will de-
crease the final amount of functional GFP and vice versa,
allowing to screen for promoters or inhibitors of the pro-
tein aggregation process.
Detection of the Aβ42 aggregation-promoting effect of
ionic metals
Endogenous transition metals can bind amyloid peptides,
like Aβ42, promoting their aggregation and the formation
of amyloid fibers [29]. We analyzed if this pro-aggregating
effect can be monitored using the above-described ap-
proach. Purified and GuHCl denatured Aβ42wt-GFP IBs
were allowed to refold in PBS in the absence and in the
presence of Ca2+, Cu2+, Fe3+, Mg2+, Na+, Ni2+ and Zn2+. A
highly significant decrease of GFP activity was observed in
the presence of the divalent cations Cu2+, Ni2+ and Zn2+
(Figure 2A). This result validates the method since there
are strong evidences that zinc and copper enhance amyl-
oid aggregation of Aβ42 and are a component of the senile
plaques of Alzheimer's disease patients [30]. In the case of
nickel, despite being a metal that lacks physiological rele-
vance, it has also been described to bind Aβ42 and en-
hance the peptide cytotoxicity, via nanoscale oligomer
formation, with the same potency than Cu+2 [29]. Neither
Zn+2 nor Cu+2 quenched the fluorescence of native
untagged GFP (Figure 2B). Moreover, although the pres-
ence of Zn+2 and Cu+2 reduced untagged GFP fluorescence
recovery, its effect was clearly lower than the one exerted
on the refolding of Aβ42wt-GFP IBs (Figure 2B), indicating
that in both cases the Aβ42 peptide is a main player in the
observed metal promoted aggregation. We analyzed the
presence and morphology of aggregates in refolding solu-
tions in the presence and absence of Zn+2 and Cu+2 by
Transmission Electron Microscopy (Figure 3A). In contrast
to intact IBs, which appear as electrodense spherical indi-
vidual entities, all the aggregates in refolding solutions had
an amorphous morphology. Nevertheless, Fourier Trans-
formed Infrared Spectroscopy (FT-IR) analysis of thesecondary structural features of the aggregated material
shows that, in all the cases, the spectra in the amide I re-
gion is dominated by a band at 1620–1625 cm-1, typically
attributed to the presence of intermolecular β-sheet,
which is accompanied by a minor band at 1690 cm-1
corresponding to the splitting of the main β-sheet signal
(Figure 3B). These two bands are considered a hallmark
of the presence of amyloid-like contacts. The spectra of
these aggregates are significantly different from that of na-
tive GFP, in which these signatures are absent (Figure 3B).
We explored if the approach allows visualizing a concen-
tration dependent effect of Zn+2 and Cu+2 on the aggrega-
tion of the target at cation concentrations in the range of
the physiological levels in human brain [31]. As shown in
Figure 4, the approach is highly sensitive to metal concen-
trations. The titration curves indicate that the impact of
Cu+2 on aggregation is somehow higher than that of Zn+2.
Curve fitting to one site binding equation renders apparent
dissociation constants of 0.6 and 1.9 μM for copper and
zinc, respectively. These data are in good agreement with
early reports stating that, despite the two cations bind to
equivalent sites in the Aβ peptide, the dissociation con-
stant for copper (0.4 μM) is lower than that of zinc
(1.2 μM), as measured by fluorescence and H-NMR at pH
7.2 [32]. Interestingly, despite our assay is not intended for
calculating dissociation constants, the ratio between the
copper and zinc binding values is also~ 3. Overall, the ap-
proach provides a fast qualitative assessment of metals
effect on protein aggregation.Identification of inhibitors of metal-triggered Aβ42
aggregation
The identification of small molecules able to interfere
protein aggregation is one of the approaches towards
Table 1 Chemical structure of the small chemical compounds used in the present study
Compound Formula
C1 Azure C
C2 Basic blue 41
C3 Meclocycline sulfosalicylate
C4 Hemin
C5 o-Vanillin
C6 Quercetin
C7 Congo Red
C8 Thioflavin T
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Table 1 Chemical structure of the small chemical compounds used in the present study (Continued)
C9 Apigenin
C10 Nordihydroguaiaretic acid
C11 Myricetin
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http://www.microbialcellfactories.com/content/11/1/55therapeutic treatment in amyloid disorders [30,31]. In
principle, the outlined assay could be used to screen
for such compounds. In particular, in the present work
we focused in validating the approach for the identifi-
cation of inhibitors of copper and zinc promoted ag-
gregation. Despite divalent chelating molecules would
work in vitro, we discarded the study of this type of
molecules since in vivo they have shown to sequester
cofactors that are essential for the cell physiology [32].
Instead, as a test case, the IBs refolding assay was per-
formed in the presence of selected concentrations of a
collection of small compounds that have been reported
previously to bind synthetic amyloid Aβ peptides or to
modulate their aggregation and/or toxicity [33–37] but
have never been assayed before in the presence of metals.
The chemical formulae of the different compounds are
shown in Table 1. Among the twelve tested compounds
only meclocycline sulfosalicylate promoted a significant
change in the final levels of GFP fluorescence in the
presence of cooper (Figure 5A). This compound was also
active in the presence of zinc but the strongest effect in
the presence of this cation was observed for o-Vanillin (2-
Hydroxy-3-methoxybenzaldehyde) (Figure 5B). o-Vanillin
has a cyclic structure that might quench GFP fluores-
cence. Effectively, the presence of 25 μM concentration
of the compound quenched 15 % of the native untagged
GFP fluorescence (Figure 5C). We monitored the effect
of o-Vanillin on the refolding of Aβ42wt-GFP IBs in the
absence of metals. The compound did not exhibit any
positive effect on GFP recovery by itself and again a17 % decrease in final fluorescence, mostly attributable
to quenching, was observed. Overall, these data indicate
that the presence of the compound reduces the metal-
promoted aggregation effect by more than 15 fold,
allowing to recover about 95% of the GFP-fluorescence
observed in the absence of zinc and presence of o-Vanillin
(Figure 5D). Interestingly, the o-Vanillin effect seems to
be specific for zinc, with a negligibly effect for copper.
This result is in agreement with previous data indicating
that zinc and copper Aβ42 induced aggregation pathways
differ in the nature of their intermediate species and sug-
gest that the natural product o-Vanillin targets specifically
zinc promoted misfolding intermediates, which are char-
acterized by a larger exposition of hydrophobic residues
relative to those promoted by copper [38].
Although, to our knowledge, no in vivo effects of
o-Vanillin on Aβ42 promoted neuronal toxicity have
been reported so far (work in progress). A closely
related compound differing only in a CH2 group, 2-
Hydroxy-3-ethoxybenzaldehyde, completely blocked
the neurotoxicity of the peptide to rat hippocampal
neurons in culture [39], indicating that despite the
simplicity of our assay, it may identify physiologically
relevant hit compounds.
To obtain further insights on the effects of copper,
zinc and o-Vanillin on Aβ42 aggregation, we monitored
the kinetics of GFP refolding after IBs denaturation in
the presence and absence of these molecules by follow-
ing the changes in fluorescence emission (Figure 5E). In
PBS, GFP fluorescence was recovered following a
Villar-Piqué et al. Microbial Cell Factories 2012, 11:55 Page 8 of 11
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0.90 ± 0.02 s-1 and a half-life of 46.21 min for the fast re-
action phase. The presence of both copper and zinc
abrogated completely the fluorescence recovery already
at the beginning of the refolding reaction, likely indicat-
ing that they promote a very fast aggregation of the fu-
sion protein that totally competes the GFP domain
folding reaction. The presence of o-Vanillin has a negligible
effect on copper containing solutions. In contrast, this mol-
ecule allows recovery of 70 % of the fluorescence at the
end of the reaction in the presence of zinc. The rate con-
stants and half-life for the fast phase were very close to
those exhibited in the absence of metals, with values of
0.87±0.03 s-1 and 48.29 min, respectively. This indicates
that this compound acts interfering with zinc promoted
Aβ42 aggregation without affecting GFP folding. Inter-
estingly, the GFP fluorescence recovery reaction is com-
pleted after 3.5 h, being thus a faster assay than thoseA
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Figure 5 Fluorescence recovery in the presence of small chemical com
100-fold in PBS in the absence or presence of 25 μM Cu+2 (A) and Zn+2 (B
25 μM final concentration: azure C (C1), basic blue 41 (C2), meclocycline su
congo red (C7), thioflavin –T (C8), apigenin (C9), nordihydroguaiaretic acid
untagged GFP fluorescence by 25 μM o-Vanillin. (D) Comparative effect of
fluorescence recovery upon dilution of denatured Aβ42wt-GFP IBs. (E) GFP
IBs in PBS (black solid circles) and PBS with 25 μM Cu+2 (red) or Zn+2 (blue
25 μM o-Vanillin.relying on the aggregation of synthetic peptides, which
usually require at least overnight incubation [40]. We
used the metallochromic Zincon reagent [41] to quantify
the free levels of Zn2+ and Cu2+ in the absence and
presence of o-Vanillin using spectrophotometry. No dif-
ferences in free ion metal levels were observed (data not
shown) suggesting that the compound does not act as a
chelator but rather affects the refolding/aggregation kin-
etics of misfolded GFP fusions.
Conclusions
Based in our previous knowledge on the amyloid-like
nature of the IBs formed by Aβ peptides [16,23] and
the in vivo correlation between the aggregation rates
and the total IBs activity [22,26], we describe here a
straightforward approach to identify compounds that
modulate Aβ aggregation using bacterial IBs. The
method is implemented using 96 well plates and theB
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) and in the presence of the following small chemical compounds at
lfosalicylate (C3), hemin chloride (C4), o-Vanillin (C5), quercetin (C6),
(C10), myricetin (C11) and curcumin (C12). (C) Quenching of native
the absence or presence of 25 μM o-Vanillin and/or Zn+2 on GFP
fluorescence recovery kinetics upon dilution of denatured Aβ42wt-GFP
) ions in the absence (solid circles) or presence (empty circles) of
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http://www.microbialcellfactories.com/content/11/1/55reaction takes less than four hours, making it suitable
for high-throughput screening (Figure 6). Because most
amyloid proteins and peptides form IBs when expressed
in bacteria [17], the approach may have, in principle, a
broad applicability in the search for aggregation modula-
tors in conformational disorders. The assay does not re-
quire a detailed understanding of the structure of theFigure 6 Outline of the screening method to identify molecules able
kinetic competition between the aggregation promoted by the Aβ42 moie
of Aβ42wt-GFP IBs. Molecules that accelerate the aggregation reaction resuaggregating species, and can provide an unbiased method
for the discovery of hit compounds. IBs can be produced
and purified in large amounts, making the method cost-
effective, especially when compared with the use of syn-
thetic peptides. Despite its simplicity, the approach
allows to distinguish between aggregation pathways and
to identify inhibitors with therapeutic potential.to modulate amyloid aggregation. The method is based on the
ty and the folding of the GFP domain after denaturation and refolding
lt in low fluorescence recovery and vice versa.
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Production and purification of inclusion bodies
Escherichia coli BL21DE3 competent cells were trans-
formed with pET28 vectors (Novagen, Inc., Madison, WI,
USA) encoding the sequences for Aβ42wt-GFP fusion and
the mutant Aβ42F19D-GFP, as previously described
[25].
10 mL of bacterial cultures were grown at 37°C
and 250 rpm in LB medium containing 50 μg/mL of
kanamycin. At an OD600 of 0.5, 1 mM of isopropyl-
β-D-1-thiogalactopyranoside (IPTG) was added to in-
duce recombinant protein expression.
After 4 hours, cells were harvested by centrifugation
and pellets were re-suspended in lysis buffer (100 mM
NaCl, 1 mM EDTA and 50 mM Tris pH 8) to purify intra-
cellular inclusion bodies (IBs), as previously described
[41]. Briefly, protease inhibitor PMSF and lysozyme were
added at the final concentrations of 15 mM and
300 μg/mL, respectively. After incubating at 37°C for
30 min, detergent NP-40 was added at 1 % and cells
were incubated at 4°C for 50 min under mild agitation.
To remove nucleic acids, cells were treated with DNase
and RNase at 15 μg/mL at 37°C for 30 min. IBs were
collected by centrifugation at 12,000xg for 10 min and
washed with lysis buffer containing 0.5 % Triton X-100.
Finally, they were washed three times with PBS to re-
move remaining detergent.
In vitro refolding assay
15 μL of purified IBs at OD360 = 10 were centrifuged for
10 min at 12000xg. To denature the aggregates, the pel-
lets were re-suspended in 10 μL of 8 M GuHCl or 10 M
urea and incubated at room temperature for 4 h. For the
refolding process, denatured aggregates were dissolved in
990 μL of refolding buffer. These buffers were based on
PBS, previously treated with Chelex 100 chelating resin
from Sigma-Aldrich (St. Louis, MO, USA), and the fol-
lowing salts and compounds according to the different
refolding assays: CaCl2, FeCl3, MgCl2, NaCl, NiCl2,
ZnCl2, CuCl2, apigenin, azure C, basic blue 41, congo
red, curcumin, hemin chloride, meclocycline sulfosa-
licylate, myricetin, nordihydroguaiaretic acid, o-Vanillin
(2-hydroxy-3-methoxybenzaldehyde), thioflavin -T and
quercetin, all obtained from Sigma-Aldrich (St. Louis,
MO, USA). Equimolar concentrations of purified untagged
GFP were used in control experiments. GFP fluorescence
of the solutions containing refolded IBs or untagged GFP
were measured in a 96 well plate in a Victor 3 Plate Reader
(Perkin-Elmer, Inc., Waltham, MA, USA) using excitation
and emission wavelength filters of 405 nm and 510 nm, re-
spectively or in a Jasco FP-8200 spectrofluorometer using
excitation and emission wavelengths of 480 nm and
510 nm, respectively. Measurements were performed in
triplicate. For kinetic experiments, the refolding step wasfollowed using the same parameters and reading the fluores-
cence emission every 2 min for 16 h. In order to
homogenize the samples, these were briefly shacked (for
5 s) before each determination.
Transmission electronic microscopy
IBs or aggregates containing solutions were placed on car-
bon-coated copper grids, and left to stand for five minutes.
The grids were washed with distilled water and stained
with 2 % (w/v) uranyl acetate for another two minutes be-
fore analysis using a HitachiH-7000 transmission electron
microscope (Hitachi, Tokyo, Japan) operating at accelerat-
ing voltage of 75 kV.
Secondary structure determination
Aggregates present in refolding solutions were precipi-
tated by centrifugation at 12.000 xg (g en cursiva i sense
espais) for 30 min, resuspended in Milli-Q water and ana-
lyzed, together with purified untagged GFP, by FT-IR spec-
troscopy using a Bruker Tensor 27 FT-IR Spectrometer
(Bruker Optics Inc) with a Golden Gate MKII ATR
accessory. Each spectrum consists of 16 independent
scans, measured at a spectral resolution of 2 cm-1 within
the 1700–1500 cm-1 range. All spectral data were acquired
and normalized using the OPUS MIR Tensor 27 software.
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